101 related articles for article (PubMed ID: 31062943)
1. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
Guadagni S; Fiorentini G; Palumbo P; Masedu F; Ricevuto E; Bruera G; Deraco M; Kusamura S; Sarti D; Fiorentini C; Gailhofer S; Clementi M
Minerva Chir; 2019 Aug; 74(4):304-312. PubMed ID: 31062943
[TBL] [Abstract][Full Text] [Related]
2. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Guadagni S; Clementi M; Bencivenga M; Kusamura S; Fiorentini C; Masedu F
Updates Surg; 2018 Dec; 70(4):441-447. PubMed ID: 30191532
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer.
Guadagni S; Fiorentini G; Palumbo G; Valenti M; Russo F; Cantore M; Deraco M; Vaglini M; Amicucci G
Arch Surg; 2001 Jan; 136(1):105-12. PubMed ID: 11146790
[TBL] [Abstract][Full Text] [Related]
4. Pelvic perfusion for locally recurrent unresectable rectal tumors.
Unal AE; Bayar S; Tez M; Gocmen E; Kocaoglu H; Akgul H
Hepatogastroenterology; 2005; 52(63):757-60. PubMed ID: 15966199
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Guadagni S; Fiorentini G; Clementi M; Palumbo P; Mambrini A; Masedu F
Updates Surg; 2017 Sep; 69(3):403-410. PubMed ID: 28791628
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study.
Guadagni S; Fiorentini G; Mambrini A; Masedu F; Valenti M; Mackay AR; Sarti D; Ricevuto E; Clementi M; Catarci M; Lazzarin G; Bruera G
Oncotarget; 2019 Jun; 10(39):1-13. PubMed ID: 31231460
[TBL] [Abstract][Full Text] [Related]
7. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Wanebo HJ; DiSiena M; Begossi G; Belliveau J; Gustafson E
Ann Surg Oncol; 2008 Apr; 15(4):1107-16. PubMed ID: 18157578
[TBL] [Abstract][Full Text] [Related]
8. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Turk PS; Belliveau JF; Darnowski JW; Weinberg MC; Leenen L; Wanebo HJ
Arch Surg; 1993 May; 128(5):533-8; discussion 538-9. PubMed ID: 7683872
[TBL] [Abstract][Full Text] [Related]
9. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: a phase II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Caterino GP; Di Giuro G; Amicucci G
Eur J Surg Oncol; 2007 Feb; 33(1):72-8. PubMed ID: 17166688
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Guadagni S; Aigner KR; Palumbo G; Cantore M; Fiorentini G; Pozone T; Deraco M; Clerico M; Chaudhuri PK
J Clin Pharmacol; 1998 Oct; 38(10):936-44. PubMed ID: 9807975
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
[TBL] [Abstract][Full Text] [Related]
13. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Guadagni S; Fiorentini G; De Simone M; Masedu F; Zoras O; Mackay AR; Sarti D; Papasotiriou I; Apostolou P; Catarci M; Clementi M; Ricevuto E; Bruera G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):205-219. PubMed ID: 31620896
[TBL] [Abstract][Full Text] [Related]
14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
15. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique.
Wanebo HJ; Chung MA; Levy AI; Turk PS; Vezeridis MP; Belliveau JF
Ann Surg Oncol; 1996 May; 3(3):295-303. PubMed ID: 8726186
[TBL] [Abstract][Full Text] [Related]
16. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
Guadagni S; Santinami M; Patuzzo R; Pilati PL; Miotto D; Deraco M; Rossi CR; Fiorentini G; Di Filippo F; Valenti M; Amicucci G
Melanoma Res; 2003 Feb; 13(1):51-8. PubMed ID: 12569285
[TBL] [Abstract][Full Text] [Related]
17. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
van Ijken MG; van Etten B; Guetens G; de Bruijn EA; Ten Hagen TL; Wiggers T; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):897-904. PubMed ID: 16084053
[TBL] [Abstract][Full Text] [Related]
18. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
Guadagni S; Russo F; Rossi CR; Pilati PL; Miotto D; Fiorentini G; Deraco M; Santinami M; Palumbo G; Valenti M; Amicucci G
Am J Surg; 2002 Jan; 183(1):28-36. PubMed ID: 11869699
[TBL] [Abstract][Full Text] [Related]
19. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
20. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
Corn BW; Lanciano RM; Boente M; Hunter WM; Ladazack J; Ozols RF
Cancer; 1994 Dec; 74(11):2979-83. PubMed ID: 7525039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
